Background: 10 days of amoxicillin/clavulanic acid high dose and 5 days of cefdinir have been the preferred first-or second-line antibiotics for treatment of children with acute otitis media (AOM) since 2004, as recommended by the American Academy of Pediatrics in the USA, but no head-to-head comparison study has been done. Objective: The purpose of the study was to compare the clinical efficacy of amoxicillin/clavulanic acid high-dose therapy for 10 days with cefdinir therapy for 5 days for AOM at recommended doses. Methods: This was an investigator-blind trial in young children 6-24 months old with no history of recurrent AOM who were randomly assigned to amoxicillin/ clavulanic acid (80 mg/kg/day amoxicillin) or cefdinir (14 mg/kg/day), both in two divided doses.
5 were lost to follow-up. High-dose amoxicillin/clavulanic acid-treated children had a better cure rate (86.5%) than cefdinir-treated patients (71.0%; p = 0.001). Cefdinir was correlated with less frequent cure outcomes as children increased in age between 6 and 24 months. The odds ratios for clinical cure per increasing month of age estimated from a logistic regression model for amoxicillin/clavulanic acid high dose and cefdinir treatment groups was 0.992 (95% CI 0.932, 1.056), p > 0.05 and 0.932 (95% CI 0.881, 0.986), p = 0.01. The differences in the odds ratios are significant at p < 0.002, indicating a stable clinical cure rate across the ages of children studied for amoxicillin/clavulanic acid and decreasing clinical cure rates as children increased in age for cefdinir. Conclusion: In children with bona fide AOM for whom clinical outcomes are assessed by validated otoscopists, 10 days of high-dose amoxicillin/clavulanic acid is significantly more effective than 5 days of cefdinir as therapy for AOM. Because of the identified age effect (correlated to child weight), higher doses of cefdinir may have led to a different conclusion; 10 days of cefdinir may also have led to a different conclusion.
Background
In 2004, the American Academy of Pediatrics (AAP) and the American Academy of Family Physicians (AAFP) recommended amoxicillin/ clavulanic acid high dose and cefdinir as preferred antibiotics for treatment of children with acute otitis media (AOM). [1] The forthcoming 2012 AAP/AAFP guidelines will make the same recommendation.
In this paper, we describe a head-to-head comparison of amoxicillin/clavulanic acid high dose versus cefdinir as 10-and 5-day treatments, respectively, for AOM in children. Both are approved antibiotic treatments for AOM, and the studied durations and dosages of treatment are approved US FDA regimens.
Methods

Study Setting
The study took place at Legacy Pediatrics, Rochester, NY, USA, and Kentucky Pediatric Research, Bardstown, KY, USA. Both sites had two investigators who are validated expert otoscopists. The sociodemographics of the patient populations of the two sites differ. Legacy Pediatrics cares for a predominantly suburban, higher socioeconomic status population, while the Bardstown Kentucky Pediatric Research group cares for a predominantly rural, lower socioeconomic status population.
Study Design and Patient Population
This was a prospective, randomized, investigatorblind trial that included children aged 6-24 months with AOM enrolled from the above-mentioned two sites. The study was conducted from January 2003 to May 2005.
The diagnosis of AOM was based on examination with pneumatic otoscopy that identified a bulging or full tympanic membrane; and the presence of purulent middle-ear effusion, and reduced tympanic membrane mobility as documented by both pneumatic otoscopy and an abnormal tympanogram (as evidenced by a 'B' or 'C' curve). Symptoms of otalgia, irritability, and fever were assessed at diagnosis and test-of-cure (TOC). Four of the authors (JC, SB, JH and MP) were the clinical investigators (validated otosco-pists) who made the diagnosis of AOM on study entry and determined clinical outcome (see the Interventions and Assessments section).
Exclusion criteria were children with chronic otitis media, chronic middle-ear effusion, ventilation tubes, perforated tympanic membranes or otorrhea, and patients with 'A' or 'B' curves with obvious dry perforation (high volume).
The study was approved by an investigational review board (Western IRB, Seattle, WA, USA), and written informed consent was obtained.
Interventions and Assessments
Antibiotic treatment consisted of amoxicillin/ clavulanic acid high dose (80 mg/kg/day amoxicillin divided twice daily) or cefdinir (14 mg/kg/day divided twice daily). High-dose amoxicillin/clavulanic acid was given for 10 days and cefdinir for 5 days. Each AOM research site used an independent computer-generated random number table to allocate subjects.
Symptoms and signs were recorded at two assessment visits: one at the time of diagnosis and a second at the TOC visit 11-14 days later. The same otoscopist carried out both assessments for each child using 10-and 30-point symptom scoring systems at each visit. [2] The determination of compliance was monitored by use of a Medical Electronic Monitoring System (MEMS) cap dispenser and measurement of antibiotic volume remaining at the TOC visit. The per protocol analysis required a minimum of 80% compliance with the prescribed dosing regimen.
Outcome
Subjects were classified as having clinical cure, failure, or an indeterminate outcome at TOC based upon symptoms and examination findings.
Clinical Cure
Participants were considered to have clinical cure if they met the following criteria:
they received the prescribed dosing regimen during the first 72 hours of the study and met the following; their body temperature at the TOC visit was £38°C if the temperature was measured rectally or aurally, £37.5°C if measured orally, or £37.3°C if measured at the axilla; otoscopic examination of the tympanic membrane was rated as improved by the investigator at the visit, with no evidence of fullness or bulging of the tympanic membrane (the presence of middle-ear effusion was acceptable); no antibiotic was given for AOM and no surgical procedure was performed for AOM on or before the TOC visit; no indeterminate criteria applied.
Clinical Failure
Subjects were considered to have clinical failure at the TOC visit if they had received the prescribed dosing regimen during the first 72 hours of the study, did not meet any other indeterminate criteria, and one of the following conditions were met:
an additional antibiotic was prescribed for AOM on or before the TOC visit; a surgical procedure was performed for AOM on or before the TOC visit; there was evidence of fullness or bulging of the tympanic membrane; perforation of the tympanic membrane on or before the TOC visit; the subject had unsatisfactory resolution of signs and symptoms of AOM according to the investigator.
Indeterminate Outcome
A participant was classified as having an indeterminate outcome at the TOC visit and dropped from the analysis at TOC if <80% of the prescribed treatment was taken, or there were inadequate data to assess clinical outcome due to lack of follow-up.
Statistics
Association of cure rate and age, and any interaction with treatment was quantitatively estimated using a fully determined logistic regression model, permitting the estimation-specific age gradients, as well as formal statistical tests for treatment differences in age gradients. Estimates of the age gradient are given in the form of odds ratios (ORs) for cure rates associated with an increase in age of 1 month, and are obtainable directly from model parameters.
Results
A total of 330 children were enrolled in the study, and their average age was 13.1 months (SD -4.9); 105 and 225 children were enrolled at the New York and Kentucky sites, respectively. There were 165 children in each treatment group; 325 children were evaluated at the TOC visit and five subjects were lost to follow-up. Table I shows the overall assessment of clinical outcome for the two antibiotic regimens. The clinical cure rate with amoxicillin/clavulanic acid high dose (86.5%) was significantly higher than that with cefdinir (71.0%) [p = 0.001]. Figure 1 shows an analysis of the variation in cure rate of amoxicillin/clavulanic acid high dose and cefdinir according to the age of the child. There is a significant difference between the two antibiotics (p < 0.002). The difference in efficacy with high-dose amoxicillin/clavulanic acid between the ages of 6 and 24 months in the children treated did not impact the overall cure rate (OR 0.87 [95% CI 0.28, 2.69]; p = 0.8). In contrast, the difference in efficacy with cefdinir between the ages of 6 and 24 months in the children treated did adversely impact the overall cure rate (OR 0.28 [95% CI 0.10, 0.78]; p = 0.01).
In table II, the ORs of clinical cure as estimated from a logistic regression model are presented. For each increasing month of age, the OR for cure remained stable for treatment with highdose amoxicillin/clavulanic acid but significantly declined for treatment with cefdinir (p = 0.01). Thus, if the odds of cure were considered to be 100% at age 6 months, then 1 month later the odds for cure would decrease to 93.2% (95% CI 88.1, 98.6), and for each subsequent month the odds of cure would decrease by another 93.2% compared with the prior month. Table III shows the symptoms and otoscopic signs at both the initial and the TOC visits at the two study sites. Given the age of the study participants, at enrollment approximately half could not complain of ear pain but more than half had a history of irritability. Nearly 100% of subjects had tympanic membrane erythema, decreased tympanic membrane mobility, abnormal effusion colour, and a full/bulging tympanic membrane. Nearly all signs of AOM were absent at the TOC visit in the cured children, with the exception of decreased tympanic membrane mobility, reflecting persistence of middle-ear effusion.
Compliance exceeded 80% for evaluable subjects per protocol. Details of the compliance aspect of the study and use of MEMS cap monitoring will be published elsewhere (Block et al., unpublished results).
Discussion
Amoxicillin/clavulanic acid high dose and cefdinir are recommended as first-and/or secondline antibiotic choices for AOM in children according to the recommendations of the AAP/AAFP guidelines for AOM management. Although there have been prior studies of amoxicillin/clavulanic acid and cefdinir as treatment of AOM, [3, 4] this is the first study to compare amoxicillin/clavulanic acid high dose for 10 days versus cefdinir for 5 days, both of which are approved regimens for AOM in children.
The superior outcome with 10 days of amoxicillin/clavulanic acid high dose compared with 5 days of cefdinir could be predicted by in vitro testing of the drugs against the dominant otopathogens of AOM. [5] Although tympanocentesis was not performed in this trial, the pathogen mix in children with AOM in this age group and the antibiotic susceptibility of those pathogens has been extensively characterized over long time periods at both centres, including the contemporaneous time period of the current study. [6] [7] [8] The better efficacy observed with high-dose amoxicillin/clavulanic acid must be taken in the context that these children were in a clinical trial where compliance was very high. In comparison, in everyday clinical practice, the greater incidence of adverse events such as gastrointestinal upset and diarrhoea with amoxicillin/clavulanic acid high dose compared with cefdinir, as well as the marginal taste of amoxicillin/clavulanic acid high dose should be factors considered when prescribing amoxicillin/ clavulanic acid high dose for children. [1, 9] Our study has strengths and limitations. The study design was prospective, randomized and investigator blinded. The four participating clinicians in this study are highly skilled, validated otoscopists; therefore clinical diagnosis at study entry and at TOC would likely have a high correlation (>90% for all four investigators, data not shown) with tympanocentesis results. Entry into AOM clinical trials based on a clinical diagnosis and outcome assessment has the potential to result in the 'Pollyanna phenomena'. [10] Indeed, such a study design has the potential to disguise true differences in antibiotic comparative trials when sample sizes are small. However, in our study, the sample size proved adequate to show a statistically significant difference between the two treatments. We contend that this may have occurred because of the diagnostic skill of the otoscopists at study entry and at TOC. Furthermore, a multicentre, open-label, non-comparator, tympanocentesis study of AOM of 447 children at risk for persistent and recurrent AOM treated with a higher dosage of cefdinir (25 mg/kg/day once daily) for a longer duration than our trial (10 days) was described by Arguedas et al. [11] They found that, at higher doses administered for 10 days, the bacteriological eradication rate, based on repeat tympanocentesis, was 91%, 67% and 43% for Streptococcus pneumoniae that were penicillin susceptible, penicillin intermediate and penicillin resistant, respectively.
Conclusion
Our results show that 10 days of treatment with high-dose amoxicillin/clavulanic acid is a more effective antibiotic regimen than 5 days of cefdinir for AOM in young children. Our findings also show that the efficacy of cefdinir decreases as a child ages between 6 and 24 months and, since age of children predicts weight of the child, this observation suggests higher doses of cefdinir might produce higher clinical cure rates. We emphasize that, in clinical practice (unlike in a controlled clinical trial), the efficacy of an antibiotic also depends on compliance and that the compliance features of cefdinir are superior to those of high dose amoxicillin/clavulanic acid. Because of the identified age effect (correlated to child weight), higher doses of cefdinir may have led to a different conclusion; 10 days of cefdinir may also have led to a different conclusion. 
